Alemtuzumab reduces 1-year sustained disability: CAMS223 analysis


REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – CAMMS23 was a phase II trial comparing alemtuzumab, a monoclonal antibody that targets CD52 lymphocytes, with subcutaneous beta-interferon-1a (CAMMS223 Trial Investigators et al. N Engl J Med 2008; 359: 1786-1801; free full text at Alemtuzumab dosing groups received either 12 or 24 mg IV x 1 cycle/year. While alemtuzumab appeared to be more effective than beta-interferon (annualized relapse rate 0.10 vs. 0.36), alemtuzumab was suspended after three patients developed immune thrombocytopenia purpura (ITP).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page